06-08-2024 |
AH |
|
ACAD |
ACADIA Pharmaceuticals Inc. |
3,140 |
0.20 |
0.16 |
0.01 |
Acadia Pharma GAAP EPS of $0.20 beats by $0.03, revenue of $241.96M beats by $6.3M [8/6/2024 4:28 PM] |
15.19 |
-3.67 (-19.44%) |
15.39 |
-3.46 (-18.36%) |
14.55 - 32.59 |
6,421,052 |
2,000,000 |
69,510 |
|
|
08-05-2024 |
AH |
|
ACAD |
ACADIA Pharmaceuticals Inc. |
2,800 |
0.10 |
0.16 |
-0.27 |
Acadia Pharma GAAP EPS of $0.10 beats by $0.05, revenue of $205.83M misses by $2.75M [5/8/2024 4:10 PM] |
15.20 |
-1.93 (-11.30%) |
17.00 |
-0.13 (-0.76%) |
15.18 - 33.99 |
4,644,637 |
1,590,000 |
3,432 |
|
|
27-02-2024 |
AH |
|
ACAD |
ACADIA Pharmaceuticals Inc. |
4,070 |
0.28 |
0.32 |
-0.26 |
Acadia Pharma GAAP EPS of $0.28 misses by $0.02, revenue of $231.04M beats by $7.24M [2/27/2024 4:11 PM] |
23.64 |
-2.71 (-10.30%) |
24.55 |
-1.81 (-6.87%) |
17.71 - 33.99 |
4,274,046 |
1,740,000 |
3,036 |
|
|
02-11-2023 |
AH |
|
ACAD |
ACADIA Pharmaceuticals Inc. |
3,700 |
-0.40 |
-0.43 |
-0.17 |
Acadia Pharma GAAP EPS of -$0.40 beats by $0.05, revenue of $211.7M beats by $22.08M [11/2/2023 4:15 PM] |
24.09 |
1.11 (4.81%) |
23.81 |
0.82 (3.57%) |
13.73 - 33.99 |
2,253,713 |
1,420,000 |
19,364 |
|
|
02-08-2023 |
AH |
|
ACAD |
ACADIA Pharmaceuticals Inc. |
4,760 |
0.01 |
-0.12 |
-0.21 |
Acadia Pharma GAAP EPS of $0.01 beats by $0.07, revenue of $165.3M beats by $7.46M [8/2/2023 4:15 PM] |
27.29 |
-1.91 (-6.54%) |
27.86 |
-1.34 (-4.59%) |
13.73 - 33.99 |
3,303,660 |
1,870,000 |
2,286 |
|
|
08-05-2023 |
AH |
4:05 PM ET (May 8) |
ACAD |
ACADIA Pharmaceuticals Inc. |
3,500 |
-0.27 |
-0.21 |
-0.70 |
ACADIA Pharma GAAP EPS of -$0.27 misses by $0.06, revenue of $118.46M misses by $1.83M [5/8/2023 4:07 PM] |
21.43 |
-0.12 (-0.53%) |
21.67 |
0.12 (0.56%) |
12.24 - 22.11 |
1,470,706 |
1,270,000 |
26,428 |
|
|
27-02-2023 |
AH |
4:05 PM ET (Feb 27) |
ACAD |
ACADIA Pharmaceuticals Inc. |
3,070 |
-0.26 |
-0.25 |
-0.27 |
ACADIA Pharma GAAP EPS of -$0.26 misses by $0.02, revenue of $136.49M beats by $1.31M [2/27/2023 4:08 PM] |
20.72 |
1.32 (6.81%) |
19.40 |
0.0 (0.00%) |
12.24 - 28.06 |
2,749,815 |
1,240,000 |
257,073 |
|
|
02-11-2022 |
AH |
4:05 PM ET (Nov 2) |
ACAD |
ACADIA Pharmaceuticals Inc. |
2,590 |
-0.17 |
-0.18 |
-0.09 |
ACADIA Pharma GAAP EPS of -$0.17 beats by $0.02, revenue of $130.71M misses by $8.33M [11/2/2022 4:20 PM] |
14.87 |
-1.06 (-6.69%) |
15.50 |
-0.43 (-2.70%) |
12.24 - 28.05 |
3,305,095 |
1,340,000 |
148,238 |
|
|
08-08-2022 |
AH |
4:05 PM ET (Aug 8) |
ACAD |
ACADIA Pharmaceuticals Inc. |
2,330 |
-0.21 |
-0.25 |
-0.27 |
ACADIA Pharma GAAP EPS of -$0.21 beats by $0.05, revenue of $134.56M beats by $4.5M [8/8/2022 4:11 PM] |
16.23 |
-0.39 (-2.35%) |
16.35 |
-0.27 (-1.62%) |
12.24 - 28.05 |
2,566,548 |
1,830,000 |
515 |
|
|
04-05-2022 |
AH |
4:05 PM ET (May 4) |
ACAD |
ACADIA Pharmaceuticals |
2,973 |
-0.70 |
-0.49 |
0.00 |
ACADIA Pharma GAAP EPS of -$0.70 misses by $0.13, revenue of $115.5M misses by $6.72M [5/4/2022 4:24 PM] |
18.82 |
-1.07 (-5.38%) |
19.50 |
-0.39 (-1.96%) |
15.68 - 28.05 |
1,009,708 |
1,740,000 |
366 |
|
|
28-02-2022 |
AH |
4:05 PM ET (Feb 28) |
ACAD |
ACADIA Pharmaceuticals Inc. |
4,150 |
-0.27 |
-0.24 |
-0.42 |
ACADIA Pharma GAAP EPS of -$0.27 misses by $0.04, revenue of $130.8M misses by $4.64M [2/28/2022 4:10 PM] |
25.07 |
-0.34 (-1.34%) |
24.15 |
-1.26 (-4.96%) |
15.68 - 49.91 |
1,501,458 |
1,240,000 |
1,331 |
|
|
08-11-2021 |
AH |
4:05 PM ET (Nov 8) |
ACAD |
ACADIA Pharmaceuticals Inc. |
3,220 |
-0.09 |
-0.27 |
-0.54 |
ACADIA Pharma EPS beats by $0.17, beats on revenue [11/8/2021 4:24 PM] |
21.62 |
2.05 (10.48%) |
20.74 |
1.17 (5.98%) |
15.68 - 57.46 |
1,518,729 |
1,270,000 |
5,416 |
|
|
04-08-2021 |
AH |
4:10 PM ET (Aug 4) |
ACAD |
ACADIA Pharmaceuticals Inc. |
3,360 |
-0.27 |
-0.30 |
-0.27 |
ACADIA Pharma EPS beats by $0.03, misses on revenue; FY21 guidance lowered [8/4/2021 4:22 PM] |
19.38 |
-1.67 (-7.93%) |
19.86 |
-1.19 (-5.65%) |
19.10 - 57.46 |
2,619,131 |
1,410,000 |
23,816 |
|
|
05-05-2021 |
AH |
4:05 PM ET (May 5) |
ACAD |
ACADIA Pharmaceuticals Inc. |
3,290 |
-0.42 |
-0.53 |
-0.57 |
ACADIA Pharma EPS beats by $0.12, misses on revenue [5/5/2021 4:15 PM] |
20.94 |
1.54 (7.94%) |
19.50 |
0.10 (0.52%) |
19.20 - 58.72 |
2,298,534 |
1,680,000 |
3,614 |
|
-
The Gross Law Firm Announces Class Actions on Behalf of Shareholders of RIDE, ROOT and ACAD [May-04-21 03:40PM]
-
SHAREHOLDER ACTION NOTICE: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against ACADIA Pharmaceuticals Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm [May-04-21 03:00PM]
-
The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of DOX, CAN and ACAD [May-04-21 02:45PM]
-
HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Updates ACAD, FGEN, RMO Investors on Securities Class Actions and Application Deadlines, Encourages Investors with Losses to Contact the Firm [May-04-21 02:00PM]
-
CLASS ACTION UPDATE for BLU, NEPT and ACAD: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders [May-04-21 11:30AM]
-
The Law Offices of Frank R. Cruz Announces the Filing of a Securities Class Action on Behalf of Acadia Pharmaceuticals Inc. (ACAD) Investors [May-04-21 11:15AM]
-
LFMD, FUV & ACAD Reminders: Bronstein, Gewirtz & Grossman LLC Reminds Shareholders of Class Actions and Encourages Investors to Contact the Firm [May-04-21 11:00AM]
-
Acadia Pharmaceuticals to Present at Upcoming Investor Conferences [May-04-21 09:00AM]
-
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Acadia Pharmaceuticals Inc. of Class Action Lawsuit and Upcoming Deadline - ACAD [May-05-21 11:42AM]
-
CLASS ACTION UPDATE for RMO, CS and ACAD: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders [May-05-21 12:10PM]
-
INVESTOR ACTION ALERT: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against ACADIA Pharmaceuticals Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm [May-05-21 02:00PM]
-
Lawsuits Filed Against ROOT, EBON and ACAD - Jakubowitz Law Pursues Shareholders Claims [May-05-21 02:30PM]
-
ACADIA Pharmaceuticals, Inc. to Host Earnings Call [May-05-21 02:45PM]
-
Acadia Pharmaceuticals Reports First Quarter 2021 Financial Results [May-05-21 04:10PM]
-
ACAD DEADLINE: HAGENS BERMAN, National Trial Attorneys, Alerts Acadia Pharmaceuticals (ACAD) Investors to Securities Class Action, Advises Investors with Losses to Contact Its Attorneys Now [May-05-21 05:07PM]
-
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Acadia Pharmaceuticals Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of June 18, 2021 - ACAD [May-05-21 06:39PM]
-
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Intrusion, LifeMD, Romeo Power, and Acadia Pharmaceuticals and Encourages Investors to Contact the Firm [May-05-21 10:14PM]
-
ACAD ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of June 18, 2021 in the Class Action Filed on Behalf of Acadia Pharmaceuticals Inc. Limited Shareholders [May-06-21 06:18AM]
-
ACADIA (ACAD) Q1 Earnings Beat, Revenues Fall Shy of Estimates [May-06-21 07:17AM]
-
Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Acadia Pharmaceuticals Inc. (ACAD) [May-06-21 11:31AM]
-
The Gross Law Firm Announces Class Actions on Behalf of Shareholders of CYDY, NEPT and ACAD [May-06-21 12:30PM]
-
Acadia Pharmaceuticals (ACAD) Reports Q1 Loss, Lags Revenue Estimates [May-05-21 06:05PM]
-
The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of ACAD, CCIV and PTON [May-06-21 01:45PM]
-
HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Advises ACAD, FGEN, RMO Investors with Losses to Contact the Firm, Updates on Securities Class Actions and Application Deadlines [May-06-21 04:50PM]
|
24-02-2021 |
AH |
4:05 PM ET (Feb 24) |
ACAD |
ACADIA Pharmaceuticals Inc. |
7,980 |
-0.42 |
-0.48 |
-0.34 |
ACADIA Pharma EPS beats by $0.05, misses on revenue [2/24/2021 4:07 PM] |
47.31 |
-1.38 (-2.83%) |
49.50 |
0.81 (1.66%) |
30.02 - 58.72 |
1,005,605 |
787,548 |
1,161 |
|
|
04-11-2020 |
AH |
4:05 PM ET (Nov 4) |
ACAD |
ACADIA Pharmaceuticals Inc. |
7,250 |
-0.54 |
-0.38 |
-0.29 |
ACADIA Pharma EPS misses by $0.18, beats on revenue [11/4/2020 4:08 PM] |
48.56 |
-0.57 (-1.16%) |
46.88 |
-2.25 (-4.58%) |
30.02 - 58.72 |
1,427,921 |
1,336,501 |
6,182 |
|
|
05-08-2020 |
AH |
4:05 PM ET (Aug 5) |
ACAD |
ACADIA Pharmaceuticals Inc. |
6,480 |
-0.27 |
-0.44 |
-0.38 |
ACADIA Pharma EPS beats by $0.18, beats on revenue [8/5/2020 4:07 PM] |
43.52 |
0.65 (1.52%) |
43.00 |
0.13 (0.30%) |
23.77 - 58.72 |
1,317,205 |
1,436,097 |
4,545 |
|
|